Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies

Molecular Immunology

Volumn 67, Issue 2, 2015, Pages 58-66

  Zugmaier, Gerhard ^a   Klinger, Matthias ^a   Schmidt, Margit ^a   Subklewe, Marion ^b,c  

^a Amgen Research GmbH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c German Res Cen for Env Health/Clin Coop Gr Hematopoietic Cell Transplantation (CCG HCT)   (Germany)

Author keywords

ALL; AMG 330; AML; BiTE; Blinatumomab; Immunotherapy; NHL

Indexed keywords

AMG 330; ANTINEOPLASTIC AGENT; BLINATUMOMAB; CD19 ANTIGEN; CD33 ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL EXPANSION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL EVALUATION; CYTOTOXIC T LYMPHOCYTE; DRUG BLOOD LEVEL; DRUG RESPONSE; EX VIVO STUDY; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RELAPSED REFRACTORY B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; REVIEW; T LYMPHOCYTE; TARGET CELL; DISEASE FREE SURVIVAL; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; METABOLISM; TREATMENT OUTCOME;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HEMATOLOGIC NEOPLASMS; HUMANS; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84939464191     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.02.033     Document Type: Review

References (62)

1. Aigner M., Feulner J., Schaffer S., Kischel R., Kufer P., Schneider K., Henn A., Rattel B., Friedrich M., Baeuerle P.A., Mackensen A., Krause S.W. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013, 27:1107-1115.
2. Bader P., Kreyenberg H., Henze G.H.R., Eckert C., Reising M., Willasch A., Barth A., Borkhardt A., Peters C., Handgretinger R., Sykora K.-W., Holter W., Kabisch H., Klingebiel T., von Stackelberg A. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J. Clin. Oncol. 2009, 27:377-384.
3. Baessler T., Charton J.E., Schmiedel B.J., Grunebach F., Krusch M., Wacker A., Rammensee H.G., Salih H.R. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010, 115:3058-3069.
4. Baessler T., Krusch M., Schmiedel B.J., Kloss M., Baltz K.M., Wacker A., Schmetzer H.M., Salih H.R. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res. 2009, 69:1037-1045.
5. Baeuerle P.A., Kufer P., Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr. Opin. Mol. Ther. 2009, 11:22-30.
6. Baeuerle P.A., Reinhardt C., Kufer P. BiTE: a new class of antibodies that recruit T-cells. Drugs Future 2008, 33:137.
7. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., Noppeney R., Viardot A., Hess G., Schuler M., Einsele H., Brandl C., Wolf A., Kirchinger P., Klappers P., Schmidt M., Riethmuller G., Reinhardt C., Baeuerle P.A., Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977.
8. Bassan R., Spinelli O., Oldani E., Intermesoli T., Tosi M., Peruta B., Rossi G., Borlenghi E., Pogliani E.M., Terruzzi E., Fabris P., Cassibba V., Lambertenghi-Deliliers G., Cortelezzi A., Bosi A., Gianfaldoni G., Ciceri F., Bernardi M., Gallamini A., Mattei D., Di Bona E., Romani C., Scattolin A.M., Barbui T., Rambaldi A. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009, 113:4153-4162.
9. Borowitz M.J., Devidas M., Hunger S.P., Bowman W.P., Carroll A.J., Carroll W.L., Linda S., Martin P.L., Pullen D.J., Viswanatha D., Willman C.L., Winick N., Camitta B.M., Children's Oncology Group Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008, 111:5477-5485.
10. Brandl C., Haas C., d'Argouges S., Fisch T., Kufer P., Brischwein K., Prang N., Bargou R., Suzich J., Baeuerle P.A., Hofmeister R. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol. Immunother. 2007, 56:1551-1563.
11. Brischwein K., Parr L., Pflanz S., Volkland J., Lumsden J., Klinger M., Locher M., Hammond S.A., Kiener P., Kufer P., Schlereth B., Baeuerle P.A. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J. Immunother. 2007, 30:798-807.
12. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., Roy S., Sridhara R., Rahman A., Williams G., Pazdur R. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 2001, 7:1490-1496.
13. Bruggemann M., Raff T., Flohr T., Gökbuget N., Nakao M., Droese J., Luschen S., Pott C., Ritgen M., Scheuring U., Horst H.A., Thiel E., Hoelzer D., Bartram C.R., Kneba M. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116-1123.
14. Burnett A., Wetzler M., Lowenberg B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 2011, 29:487-494.
15. Coles S.J., Wang E.C., Man S., Hills R.K., Burnett A.K., Tonks A., Darley R.L. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011, 25:792-799.
16. Conter V., Bartram C.R., Valsecchi M.G., Schrauder A., Panzer-Grumayer R., Moricke A., Arico M., Zimmermann M., Mann G., De Rossi G., Stanulla M., Locatelli F., Basso G., Niggli F., Barisone E., Henze G., Ludwig W.D., Haas O.A., Cazzaniga G., Koehler R., Silvestri D., Bradtke J., Parasole R., Beier R., van Dongen J.J., Biondi A., Schrappe M. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115:3206-3214.
17. DeWeerdt S. Bakterien gegen Tumoren. Spek. Wissensch. 2014, 7:30-34.
18. Dreier T., Baeuerle P.A., Fichtner I., Grun M., Schlereth B., Lorenczewski G., Kufer P., Lutterbuse R., Riethmuller G., Gjorstrup P., Bargou R.C. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J. Immunol. 2003, 170:4397-4402.
19. Dreier T., Lorenczewski G., Brandl C., Hoffmann P., Syring U., Hanakam F., Kufer P., Riethmuller G., Bargou R., Baeuerle P.A. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer 2002, 100:690-697.
20. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., Rogers L.J., Gracia G.J., Jones S.A., Mangiameli D.P., Pelletier M.M., Gea-Banacloche J., Robinson M.R., Berman D.M., Filie A.C., Abati A., Rosenberg S.A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23:2346-2357.
21. Feldman E.J., Brandwein J., Stone R., Kalaycio M., Moore J., O'Connor J., Wedel N., Roboz G.J., Miller C., Chopra R., Jurcic J.C., Brown R., Ehmann W.C., Schulman P., Frankel S.R., De Angelo D., Scheinberg D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol. 2005, 23:4110-4116.
22. Frankel S.R., Baeuerle P.A. Targeting T cells to tumor cells using bispecific antibodies. Curr. Opin. Chem. Biol. 2013, 17:385-392.
23. Garber K. Bispecific antibodies rise again. Nat. Rev. Drug Discov. 2014, 13:799-801.
24. Gökbuget N., Kneba M., Raff T., Trautmann H., Bartram C.R., Arnold R., Fietkau R., Freund M., Ganser A., Ludwig W.D., Maschmeyer G., Rieder H., Schwartz S., Serve H., Thiel E., Bruggemann M., Hoelzer D., German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012, 120:1868-1876.
25. Haas C., Krinner E., Brischwein K., Hoffmann P., Lutterbuse R., Schlereth B., Kufer P., Baeuerle P.A. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009, 214:441-453.
26. Handgretinger R., Zugmaier G., Henze G., Kreyenberg H., Lang P., von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011, 25:181-184.
27. Hijazi Y., Klinger M., Schub A., Wu B., Zhu M., Kufer P., Wolf A., Nagorsen D. Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL). J. Clin. Oncol. 2013, 31(abstr):3051.
28. Hoffmann P., Hofmeister R., Brischwein K., Brandl C., Crommer S., Bargou R., Itin C., Prang N., Baeuerle P.A. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3- bispecific single-chain antibody construct. Int. J. Cancer 2005, 115:98-104.
29. Hubmann M., Kohnke T., Hoster E., Schneider S., Dufour A., Zellmeier E., Fiegl M., Braess J., Bohlander S.K., Subklewe M., Sauerland M.C., Berdel W.E., Buchner T., Wormann B., Hiddemann W., Spiekermann K. Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Haematologica 2014, 99:1317-1325.
30. Jedema I., Barge R.M., van der Velden V.H., Nijmeijer B.A., van Dongen J.J., Willemze R., Falkenburg J.H. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2004, 18:316-325.
31. Klinger M., Brandl C., Zugmaier G., Hijazi Y., Bargou R.C., Topp M.S., Gökbuget N., Neumann S., Goebeler M., Viardot A., Stelljes M., Bruggemann M., Hoelzer D., Degenhard E., Nagorsen D., Baeuerle P.A., Wolf A., Kufer P. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012, 119:6226-6233.
32. Klinger M., Kufer P., Kirchinger P., Lutterbuese P., Leo E., Reinhardt C., Baeuerle P.A., Bargou R. T cell responses during long-term continuous infusion of MT103 (MEDI-538; anti-CD19 BiTE) in patients with relapsed B-NHL: data from dose-escalation study MT103-104. Blood (ASH Annu. Meet. Abstr.) 2006, 108:2725. (abstract 903-II).
33. Klinger M., Nagorsen D., Brandl C., Wissing S., Meier P., Baeuerle P.A., Kufer P. Pharmacodynamic analyses of peripheral blood from relapsed B-NHL patients treated with anti-CD19/-CD3 bispecific BiTE® antibody blinatumomab. Haematologica 2009, 94:174-175.
34. Kohnke T., Sauter D., Ringel K., Hoster E., Laubender R.P., Hubmann M., Bohlander S.K., Kakadia P.M., Schneider S., Dufour A., Sauerland M.C., Berdel W.E., Buchner T., Wormann B., Braess J., Hiddemann W., Spiekermann K., Subklewe M. Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia 2014, 29:377-386.
35. Krupka C., Kufer P., Kischel R., Zugmaier G., Bogeholz J., Kohnke T., Lichtenegger F.S., Schneider S., Metzeler K.H., Fiegl M., Spiekermann K., Baeuerle P.A., Hiddemann W., Riethmuller G., Subklewe M. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014, 123:356-365.
36. Kung Sutherland M.S., Walter R.B., Jeffrey S.C., Burke P.J., Yu C., Kostner H., Stone I., Ryan M.C., Sussman D., Lyon R.P., Zeng W., Harrington K.H., Klussman K., Westendorf L., Meyer D., Bernstein I.D., Senter P.D., Benjamin D.R., Drachman J.G., McEarchern J.A. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013, 122:1455-1463.
37. Lichtenegger F.S., Schnorfeil F.M., Hiddemann W., Subklewe M. Current strategies in immunotherapy for acute myeloid leukemia. Immunotherapy 2013, 5:63-78.
38. Lim S.H., Vaughan A.T., Ashton-Key M., Williams E.L., Dixon S.V., Chan H.T., Beers S.A., French R.R., Cox K.L., Davies A.J., Potter K.N., Mockridge C.I., Oscier D.G., Johnson P.W., Cragg M.S., Glennie M.J. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011, 118:2530-2540.
39. Lion E., Willemen Y., Berneman Z.N., Van Tendeloo V.F., Smits E.L. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 2012, 26:2019-2026.
40. Loffler A., Kufer P., Lutterbuse R., Zettl F., Daniel P.T., Schwenkenbecher J.M., Riethmuller G., Dorken B., Bargou R.C. A recombinant bispecific single-chain antibody, CD19×CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000, 95:2098-2103.
41. Lu H., Zhou Q., Deshmukh V., Phull H., Ma J., Tardif V., Naik R.R., Bouvard C., Zhang Y., Choi S., Lawson B.R., Zhu S., Kim C.H., Schultz P.G. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew. Chem. Int. Ed. Engl. 2014, 53:9841-9845.
42. Mack M., Riethmuller G., Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7021-7025.
43. Mellor J.D., Brown M.P., Irving H.R., Zalcberg J.R., Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J. Hematol. Oncol. 2013, 6:1.
44. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
45. Muller D., Kontermann R.E. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr. Opin. Mol. Ther. 2007, 9:319-326.
46. Nagorsen D., Kufer P., Baeuerle P.A., Bargou R. Blinatumomab: a historical perspective. Pharmacol. Ther. 2012, 136:334-342.
47. Petersdorf S.H., Kopecky K.J., Slovak M., Willman C., Nevill T., Brandwein J., Larson R.A., Erba H.P., Stiff P.J., Stuart R.K., Walter R.B., Tallman M.S., Stenke L., Appelbaum F.R. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013, 121:4854-4860.
48. Raff T., Gökbuget N., Luschen S., Reutzel R., Ritgen M., Irmer S., Bottcher S., Horst H.A., Kneba M., Hoelzer D., Brueggemann M. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007, 109:910-915.
49. Rosenblat T.L., McDevitt M.R., Mulford D.A., Pandit-Taskar N., Divgi C.R., Panageas K.S., Heaney M.L., Chanel S., Morgenstern A., Sgouros G., Larson S.M., Scheinberg D.A., Jurcic J.G. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res. 2010, 16:5303-5311.
50. Schlegel P., Lang P., Zugmaier G., Ebinger M., Kreyenberg H., Witte K.E., Feucht J., Pfeiffer M., Teltschik H.M., Kyzirakos C., Feuchtinger T., Handgretinger R. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014, 99:1212-1219.
51. Schub A., Nagele V., Zugmaier G., Brandl C., Hijazi Y., Topp M.S., Kufer P., Wolf A., Klinger M. Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). J. Clin. Oncol. 2013, 31:7020. (abstract).
52. Staerz U.D., Kanagawa O., Bevan M.J. Hybrid antibodies can target sites for attack by T cells. Nature 1985, 314:628-631.
53. Stein C., Kellner C., Kugler M., Reiff N., Mentz K., Schwenkert M., Stockmeyer B., Mackensen A., Fey G.H. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br. J. Haematol. 2010, 148:879-889.
54. Taussig D.C., Pearce D.J., Simpson C., Rohatiner A.Z., Lister T.A., Kelly G., Luongo J.L., Danet-Desnoyers G.A., Bonnet D. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005, 106:4086-4092.
55. Teachey D.T., Rheingold S.R., Maude S.L., Zugmaier G., Barrett D.M., Seif A.E., Nichols K.E., Suppa E.K., Kalos M., Berg R.A., Fitzgerald J.C., Aplenc R., Gore L., Grupp S.A. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013, 121:5154-5157.
56. Topp M.S., Gökbuget N., Stein A.S., Zugmaier G., O'Brien S., Bargou R.C., Dombret H., Fielding A.K., Heffner L., Larson R.A., Neumann S., Foa R., Litzow M., Ribera J., Rambaldi A., Schiller G., Bruggemann M., Horst H.A., Holland C., Jia C., Maniar T., Huber B., Nagorsen D., Forman S.J., Kantarjian H.M. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2014, 16:57-66.
57. Topp M.S., Gökbuget N., Zugmaier G., Degenhardt E., Goebeler M.E., Klinger M., Neumann S.A., Horst H.A., Raff T., Viardot A., Stelljes M., Schaich M., Kohne-Volland R., Brueggemann M., Ottmann O.G., Burmeister T., Baeuerle P.A., Nagorsen D., Schmidt M., Einsele H., Riethmuller G., Kneba M., Hoelzer D., Kufer P., Bargou R.C. Long-term follow-up of hematological relapse-free survival in a phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL). Blood 2012, 120:5185-5187.
58. Topp M.S., Kufer P., Gökbuget N., Goebeler M., Klinger M., Neumann S., Horst H.A., Raff T., Viardot A., Schmid M., Stelljes M., Schaich M., Degenhard E., Kohne-Volland R., Bruggemann M., Ottmann O., Pfeifer H., Burmeister T., Nagorsen D., Schmidt M., Lutterbuese R., Reinhardt C., Baeuerle P.A., Kneba M., Einsele H., Riethmuller G., Hoelzer D., Zugmaier G., Bargou R.C. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 2011, 29:2493-2498.
59. Van der Velden V.H., Corral L., Valsecchi M.G., Jansen M.W., De Lorenzo P., Cazzaniga G., Panzer-Grumayer E.R., Schrappe M., Schrauder A., Meyer C., Marschalek R., Nigro L.L., Metzler M., Basso G., Mann G., Den Boer M.L., Biondi A., Pieters R., Van Dongen J.J., Interfant-99 Study Group Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009, 23:1073-1079.
60. Walter R.B. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Rev. Hematol. 2014, 7:317-319.
61. Walter R.B., Appelbaum F.R., Estey E.H., Bernstein I.D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012, 119:6198-6208.
62. Whitlock J., von Stackelberg A., Handgretinger R., Locatelli F., Rizzari C., Trippett T.M., Borkhardt A., O'Brien M.M., Rheingold S.R., Gore L. Blinatumomab in pediatric patients with relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukemia (BCP-ALL): a phase 1/2 study. Int. Soc. Paediatric Oncol. Annu. Congr. 2014.